In short
(5E)-6-(3,4-DIMETHOXYPHENYL)-3-[(2E)-3-(3,4-DIMETHOXYPHENYL)-1-OXO-2-PROPEN-1-YL]-N,N-DIETHYL-3-METHYL-4-OXO-5-HEXENAMIDE, also known by its development code TML-6, is an investigational substance being studied for the treatment of early Alzheimer’s disease. The compound is currently being evaluated in a Phase 2 clinical trial involving 210 participants, which is authorised and compares two oral doses of TML-6 against a placebo over 52 weeks.
(5E)-6-(3,4-DIMETHOXYPHENYL)-3-[(2E)-3-(3,4-DIMETHOXYPHENYL)-1-OXO-2-PROPEN-1-YL]-N,N-DIETHYL-3-METHYL-4-OXO-5-HEXENAMIDE, referred to here as TML-6, is a chemically synthesised substance that is currently under investigation as a possible treatment for early Alzheimer’s disease. The substance is not yet an authorised medicine; it is being studied in a Phase 2 clinical trial to find out whether it can affect the course of cognitive and functional decline in people with early Alzheimer’s disease.
Table of contents
Key points
- Early Alzheimer’s disease is the only condition studied in the current trial.
- The trial is in Phase 2, testing whether TML-6 has an effect in patients.
- 210 participants are planned to be enrolled in this authorised study.
- Two oral doses are being tested: 100 mg and 200 mg, compared with placebo.
- The main measure is the change in Clinical Dementia Rating – Sum of Boxes (CDR-SB) from baseline to 52 weeks.
- The trial is currently authorised, meaning it has received regulatory approval to begin.
What is TML-6?
TML-6 is the development code used in the clinical trial record for the substance (5E)-6-(3,4-DIMETHOXYPHENYL)-3-[(2E)-3-(3,4-DIMETHOXYPHENYL)-1-OXO-2-PROPEN-1-YL]-N,N-DIETHYL-3-METHYL-4-OXO-5-HEXENAMIDE. The substance is an investigational product, which means it has not received a marketing authorisation and is being tested in clinical research to determine whether it is safe and effective. No trade name is currently listed for this substance in the available trial data. The substance is being studied specifically in early Alzheimer’s disease, a condition that affects memory, thinking, and the ability to carry out everyday activities.
How does TML-6 work?
The available clinical trial record does not provide a detailed explanation of the biological mechanism of action for TML-6. The trial is designed to test whether treatment with TML-6 for 52 weeks can slow, stop, or improve cognitive and functional decline in participants with early Alzheimer’s disease compared with placebo. The exact way in which TML-6 might act in the body is not described in the registry data, and no supplementary sources are available to describe its molecular target or pharmacological pathway.
Which conditions is TML-6 studied for?
- Early Alzheimer’s disease: a stage of Alzheimer’s disease in which cognitive and functional decline has begun but is still mild. The current trial focuses on this population to see whether TML-6 can change the course of the disease.
How is TML-6 given?
In the clinical trial, TML-6 is given by mouth in the form of oral doses. The study tests two different dose levels: 100 mg and 200 mg. These are compared with a matching placebo, which has no active ingredient. The route of administration is oral, meaning the substance is taken by mouth.
What do the clinical trials show?
The clinical research programme for TML-6 consists of one authorised Phase 2 trial. This trial is interventional, meaning participants receive the study drug or placebo according to a set plan. The trial is designed to include 210 participants with early Alzheimer’s disease. The main goal is to compare the effect of TML-6 with placebo on cognitive and functional decline over 52 weeks. The primary outcome measure is the change in the Clinical Dementia Rating – Sum of Boxes (CDR-SB) from baseline to Week 52. The CDR-SB is a scale used to assess how well a person with dementia is functioning in areas such as memory, orientation, judgement, and personal care.
The trial is currently authorised, which means it has been approved by the relevant regulatory authority to proceed. No results from this trial are yet available in the registry data, so it is not possible to say whether TML-6 is effective or safe based on the current information. The trial is in Phase 2, a stage of research that typically looks at whether a treatment has a biological effect and gathers more information about safety and dosing in a larger group of patients than Phase 1.
Participants in this trial receive either TML-6 at a dose of 100 mg, TML-6 at a dose of 200 mg, or a matching placebo. The comparison with placebo allows researchers to measure the effect of TML-6 separately from any effect that might occur simply from being in a trial and receiving regular assessments.
Who can take part in this trial?
The trial is designed for people with early Alzheimer’s disease. The registry data does not provide detailed inclusion or exclusion criteria such as age range, sex, or specific diagnostic requirements. The brief summary states that the study includes participants with early Alzheimer’s disease, which typically means people in the early stages of the condition where symptoms are present but daily functioning is only mildly affected.
What is the trial measuring?
The primary outcome measure is the change in the Clinical Dementia Rating – Sum of Boxes (CDR-SB) from baseline to Week 52. The CDR-SB is a widely used tool in Alzheimer’s disease research. It provides a score that reflects a person’s cognitive and functional abilities, with higher scores indicating greater impairment. By measuring the change in this score over 52 weeks, researchers can see whether TML-6 slows, stops, or improves the decline that is typical in Alzheimer’s disease. The trial compares the change in CDR-SB between the TML-6 groups and the placebo group to determine whether the substance has a meaningful effect.
What side effects are known?
No information about side effects of TML-6 is available in the clinical trial registry data. Because the substance is still in Phase 2 research and no results have been published in the available sources, the known side effects cannot be described at this time.